(Q46390622)

21 December 2017

title

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab (English)

1 reference

21 December 2017

0 references

Vafa Shahabi

1

1 reference

21 December 2017

Gena Whitney

2

1 reference

21 December 2017

Omid Hamid

3

1 reference

21 December 2017

Henrik Schmidt

4

1 reference

21 December 2017

Scott D Chasalow

5

1 reference

21 December 2017

Suresh Alaparthy

6

1 reference

21 December 2017

Jeffrey R Jackson

7

1 reference

21 December 2017

publication date

1 March 2012

1 reference

21 December 2017

Cancer Immunology, Immunotherapy

published in

1 reference

21 December 2017

volume

61

1 reference

21 December 2017

issue

5

1 reference

21 December 2017

page(s)

733-737

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1007/s00262-012-1227-3

exact match

0 references

cites work

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

BRAF mutations in papillary carcinomas of the thyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

Genetics of melanoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

PLX4032: does it keep its promise for metastatic melanoma treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1227-3

10.1007/S00262-012-1227-3

21 January 2018

Identifiers

DOI

1 reference

21 December 2017

PubMed ID

22382362

1 reference

21 December 2017